This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Osman, I. Articles by Liew, C.-C. Search for Related Content PubMed PubMed Citation Articles by Osman, I. Articles by Liew, C.-C.

Novel Blood Biomarkers of Human Urinary Bladder Cancer

Authors' Affiliations: ¹ New York University School of Medicine; ² Memorial Sloan-Kettering Cancer Center, New York; ³ ChondroGene, Inc., Toronto, Ontario, Canada; and ⁴ Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts

Requests for reprints: Iman Osman, New York University School of Medicine, Room H-100, 550 First Avenue, New York, NY 10016. Phone: 212-686-7500, ext. 3522; Fax: 212-951-3214; E-mail: iman.osman{at}med.nyu.edu.

Purpose: Recent data indicate that cDNA microarray gene expression profile of blood cells can reflect disease states and thus have diagnostic value. We tested the hypothesis that blood cell gene expression can differentiate between bladder cancer and other genitourinary cancers as well as between bladder cancer and healthy controls.

Experimental Design: We used Affymetrix U133 Plus 2.0 GeneChip (Affymetrix, Santa Clara, CA) to profile circulating blood total RNA from 35 patients diagnosed with one of three types of genitourinary cancer [bladder cancer (n = 16), testicular cancer (n = 10), and renal cell carcinoma (n = 9)] and compared their cDNA profiles with those of 10 healthy subjects. We then verified the expression levels of selected genes from the Affymetrix results in a larger number of bladder cancer patients (n = 40) and healthy controls (n = 27).

Results: Blood gene expression profiles distinguished bladder cancer patients from healthy controls and from testicular and renal cancer patients. Differential expression of a combined set of seven gene transcripts (insulin-like growth factor–binding protein 7, sorting nexin 16, chondroitin sulfate proteoglycan 6, and cathepsin D, chromodomain helicase DNA-binding protein 2, nell-like 2, and tumor necrosis factor receptor superfamily member 7) was able to discriminate bladder cancer from control samples with a sensitivity of 83% (95% confidence interval, 67-93%) and a specificity of 93% (95% confidence interval, 76-99%).

Conclusion: We have shown that the gene expression profile of circulating blood cells can distinguish bladder cancer from other types of genitourinary cancer and healthy controls and can be used to identify novel blood markers for bladder cancer.

This article has been cited by other articles:

				M. Han, C. T. Liew, H. W. Zhang, S. Chao, R. Zheng, K. T. Yip, Z.-Y. Song, H. M. Li, X. P. Geng, L. X. Zhu, et al. Novel Blood-Based, Five-Gene Biomarker Set for the Detection of Colorectal Cancer Clin. Cancer Res., January 15, 2008; 14(2): 455 - 460. [Abstract] [Full Text] [PDF]